In PMS2-deficient cancers and adenomas, it has been shown that the KRAS mutations take place earlier in the course of development than dMMR, which may indicate that MMR deficiency does not drive the carcinogenesis in PMS2-associated CRC42–44. This evidence concerns the gene PMS2 and cancer.